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Abstract
Neurodegenerative diseases (NDDs) are increasing serious menaces to human health in
the recent years. Despite exhibiting different clinical phenotypes and selective neuronal
loss, there are certain common features in these disorders, suggesting the presence of com-
monly dysregulated pathways. Identifying causal genes and dysregulated pathways can be
helpful in providing effective treatment in these diseases. Interestingly, in spite of the consid-
erable researches on NDDs, to the best of our knowledge, no dysregulated genes and/or
pathways were reported in common across all the major NDDs so far. In this study, for the
first time, we have applied the three-way interaction model, as an approach to unravel
sophisticated gene interactions, to trace switch genes and significant pathways that are
involved in six major NDDs. Subsequently, a gene regulatory network was constructed to
investigate the regulatory communication of statistically significant triplets. Finally, KEGG
pathway enrichment analysis was applied to find possible common pathways. Because of
the central role of neuroinflammation and immune system responses in both pathogenic
and protective mechanisms in the NDDs, we focused on immune genes in this study. Our
results suggest that "cytokine-cytokine receptor interaction" pathway is enriched in all of the
studied NDDs, while "osteoclast differentiation" and "natural killer cell mediated cytotoxicity"
pathways are enriched in five of the NDDs each. The results of this study indicate that three
pathways that include "osteoclast differentiation", "natural killer cell mediated cytotoxicity"
and "cytokine-cytokine receptor interaction" are common in five, five and six NDDs, respec-
tively. Additionally, our analysis showed that Rps27a as a switch gene, together with the
gene pair {Il-18, Cx3cl1} form a statistically significant and biologically relevant triplet in the
major NDDs. More specifically, we suggested that Cx3cl1 might act as a potential upstream
regulator of Il-18 in microglia activation, and in turn, might be controlled with Rps27a in trig-
gering NDDs.
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1 Introduction
Neurodegenerative diseases (NDDs) are increasing serious menaces to human health in recent
years [1]. In spite of the considerable body of research on NDDs such as Alzheimer’s disease
(AD), amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), multiple sclerosis (MS),
Parkinson’s disease (PD) and schizophrenia (SCHIZ), effective treatment for preventing the
progressive neuronal loss is yet to be available [2].
Despite exhibiting different clinical phenotypes and selective neuronal loss in neurode-
generative abnormalities, there are many common pathological features that contribute to
these disorders, which suggest the existence of certain common pathways at the molecular
level. A few of such common pathological features are oxidative stress [3], mitochondrial dys-
function [4], glutamate excitotoxicity [5], abnormal protein aggregation [6], abnormal cellu-
lar transport [7], iron accumulation [8] and neuroinflammation [9, 10]. Therefore, it would
be interesting to survey the NDDs at once to find such a potential similarity at the molecular
level.
The number of comparative studies in NDDs is still rather low. Therefore, our knowledge
is limited to the underling common pathways and central genes in these disorders. In a few
previous studies, the major NDDs were comparatively surveyed at the systemic level. Durren-
berger and coworker generated comparative genome-wide gene expression data for six main
NDDs, namely AD, ALS, HD, MS, PD, and SCHIZ. They performed whole-genome expres-
sion analysis to look for potential common molecular pathogenic mechanisms and genes, in
addition to exclusive disease-specific changes. They reported that no dysregulated gene was
found in common across all six NDDs. Furthermore, they reported that "neuronal homeo-
static", "survival activity" and "synaptic plasticity" pathways are shared among five and four of
the diseases, respectively [11]. On the other hand, Godini and coworkers performed a compar-
ative system-level analysis on NDDs microarray data that was generated by Durrenberger and
coworkers. They constructed a protein-protein interaction network based on the co-expres-
sion approach and performed gene set enrichment analysis to find out the central factors that
are related to each disease and, in addition, those features that can be considered as the similar-
ities among them. Finally, they suggested a set of key genes that might contribute to all NDDs.
Nevertheless, in this study, similar to the above mentioned, no pathway or gene was found to
be in common across all six major NDDs [12].
In the present work, we applied the three-way interaction model to find possibly shared
genes and pathways among the major NDDs (Fig 1). High-throughput gene expression
microarray data is a form of genome-scale data that provide an opportunity to trace gene
expression patterns. There are numerous gene expression patterns which contain diverse
information about gene relations [13, 14]. One of them is cross-shaped co-expression pattern.
Such pattern is observed when the expression levels of two genes are either directly or
inversely correlated depending on the expression level (or genotype) of a third gene (i.e., the
switch gene). Three-way interaction mechanism can be inferred from a cross-shaped co-
expression pattern. In this model, the changing nature of co-expression relationship of two
genes{X1, X2} is captured by introducing a third gene (X3) which modulates the X1-X2 expres-
sion dependence. Therefore, such model can potentially shed light on some sophisticated
gene interactions that cannot be traced trace with the simplistic correlative model. In addi-
tion, three-way interaction model can provide valuable information about gene regulatory
relations [13, 15].
A significant body of evidence shows that neuroinflammation and immune system
responses have both pathogenic and protective roles in the neurological disorders [9, 16–18].
Microglia and other innate immune cells such as astrocytes with a morphologically activated
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phenotype are observed at relatively early stages in large numbers of NDDs. Such cells can be
activated in response to misfolded proteins, aberrantly localized nucleic acids or reactive oxy-
gen species (ROS) [19]. Activation of innate immune cells leads to sever inflammatory
responses in the central nervous system (CNS), renewed promoting neural damage. More spe-
cifically, Toll-like receptors (TLRs) and other pattern recognition receptors, which are
expressed on microglia, play central roles in triggering neuroinflammation. Neural damage
and subsequent inflammatory responses result in a feed-forward loop of neurodegenaration
[19].
In the present study, we focus on the immune genes to look for NDDs related mechanisms
and central switch genes that are involved in the immune responses using the three-way inter-
action model.
Fig 1. Schematic representation of the gene expression data analysis pipeline.
https://doi.org/10.1371/journal.pone.0239219.g001
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2 Materials and methods
2.1 Dataset selection and analysis
In the present work, we exploited the gene expression data reported by Durrenberger et al.
[11]. The selected dataset includes comparative genome-wide gene expression data for AD,
ALS, HD, MS, PD and SCHIZ from 118 cases of postmortem brain tissues, belonging to ento-
rhinal cortex, cervical spinal cord, ventral head of the caudate nucleus, substantia nigra, grey
matter in brodmann area, respectively. The data were generated using the Illumina human-
Ref-8 v2.0 expression bead chip platform and are available in GEO dataset under accession
number GSE26927 [11]. A brief description of the dataset was presented in S1 Table in S1
Material. The duplicated probes were removed using the genefilter package in Bioconductor
[20]. For this purpose, the mean of expression levels of duplicated probes were retained for
each gene. Finally, the probes with "immune" annotations were selected based on the Biologi-
cal Processes of the Gene Ontology annotation for the rest analysis [21].
Additionally, in order to identify differentially expressed genes (DEGs), for each disease,
theempirical Bayes t-test was performed using the LmFit function in the Limma package [22]
for each disease separately.
2.2 Determining liquid association triplets
Three-way interactions among all passible triplet combinations of genes in the dataset were
calculated using fastMLA function in fast Liquid Association package [23]. This package uses a
modified liquid association algorithm for determining changes in co-expression relations of
two genes, X1 and X2, based on the expression level of a third gene (X3).
Before running liquid association algorithm, performing two preprocessing steps on the
data is necessary: (i) normal quntile transformation [24]; (ii) standardization of mean and
standard deviation to o and 1, respectively [25] for each variable. The first preprocess was per-
formedby an in-house implementation and the second one by using CTT package [26].
False discovery rate (FDR) was estimated by using the Bonferroni correction method [27].
Subsequently, the three-way interactions with FDR< 0.01 were reported as the statistically sig-
nificant triplets.
2.3 Construction of gene regulatory network
A gene regulatory network (GRN) model provides a systematic knowledge about the complex
molecular mechanisms that control gene expression under diverse biological conditions [28].
Here, we used geWorkbench_2.6.0 software to construct GRN among all genes in dataset as
hub markers by considering p-value <0.05. Specifically, ARACNE (Algorithm for the Recon-
struction of Accurate Cellular Networks) was applied [29] to construct the GRN. This algo-
rithm uses mutual information as a measure to detect direct regulatory interactions between
each transcriptional regulator and its potential target(s).
2.4 KEGG pathway enrichment analysis
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis is a popular
statistical method to determine the validation of the shared association of a set of genes using
predefined pathways [30]. Here, KEGG pathway enrichment analysis was performed sepa-
rately for each of the six sets of DEGs using the KEGG database [31]. Above-mentioned analy-
ses were performed using ClueGO plugin [32] within the Cytoscape v.3.3.0 environment [33],
and in addition, two-sided hypergeometric test with the Bonferroni step down correction
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method and a kappa score threshold of 0.4 were considered for statistical significance
calculation.
2.5 Ethics statements
The presented study is a computational research using a public GEO dataset (accession num-
ber: GSE26927). Therefore, any ethics approval and consent statements were not required for
this study.
3 Results
3.1 Preprocessing dataset and identifying differentially-expressed genes
After preprocessing and extracting the immune-related genes from dataset, 822 genes
remained for further analysis. In order to determine differentially-expressed genes, eBayes t-
test was performed on the normalized data. By considering p-value<0.05, we selected 21, 150,
171, 111, 145 and 83 genes as significant differentially-expressed genes in AD, ALS, HD, MS,
PD and SCHIZ, respectively. The detailed results of this analysis are available in S2 Table in S1
Material.
3.2 Determining the significant cross-shaped triplets
All 822 immune-related genes were considered as potential switch genes in the fast liquid asso-
ciation analysis. The changes in FDR versus -log(p-value) for the first 300000 triplets were
showed in S3 Fig in S1 Material. In order to survey the accuracy of fastLA analysis, observed
event rate of X3 position (switch) genes in the wide range of the significant fastLA p-values
were compared with random event rate (see Fig 2). On the other hand, the relevancy of X3
position (switch) genes with DEGs was examined. As shown in Fig 3, the percentage of the
DEGs in all of the immune-related genes and the percentage of triplets that X3 position of
them is DEG in all statistically significant triplets is 25% and 53%, respectively.
With considering FDR <10−2, a set of significant cross-shaped triplets which consists of
1717 triplet combinations were selected for further analyses.
Fig 2. A survey of validity of fastLA analysis. In the wide range of the significant fastLA p-values, observed event rate
of X3 position (switch) genes were compared with random event rate. As shown, the observed event rate for switch
genes is far greater than the random one, which confirms the validity of fastLA analysis.
https://doi.org/10.1371/journal.pone.0239219.g002
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3.3 Identifying common KEEG pathway(s) in NDDs
We used GSEA in order to find common pathway(s) in NDDs in addition to detect the biolog-
ically-relevant triplets. By considering FDR<0.05 and a minimum of 3 genes in each groups,
three pathways were enriched simultaneously at least in 5 of the NDDs. All of the significantly
enriched terms based on "KEGG pathway" were presented in Fig 4A, and in addition, a
detailed information about KEGG pathway enrichment analysis was reported in S4 Table in S1
Material. Based on the results, "cytokine-cytokine receptor interaction" was enriched in all 6
NDDs, while "osteoclast differentiation", “natural killer cell mediated cytotoxicity" were
enriched in 5 of the NDDs each (Fig 4B). Based on the definition of three-way interactions in
switch mechanism model, it is expected that in biologically-relevant triplets, X1 and X2 are in
Fig 3. Relevancy of switch genes with Differentially Expressed Genes (DEGs). (A) The proportion of DEGs in all
immune-related genes; and (B) The proportion of triplets in which the X3 position is a DEG. As shown, the percentage
of DEGs in A and B is 25% and 53%, respectively. The prevalence of DEGs in the X3 position of triplets suggest that the
liquid association model is appropriate for understanding the role of DEGs in neuroinflammation.
https://doi.org/10.1371/journal.pone.0239219.g003
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the same pathway. By detecting the statistically significant triplets in the enriched terms, 89
triplets were found to be biologically relevant based on GSEA. These triplets are reported in S5
Table in S1 Material.
3.4 Detecting the cross-shaped triplets in GRN
As another attempt for analyzing the functional relevance of statistically significant triplets, we
reconstructed a GRN by ARACNE. By considering p-value<0.05, the GRN included 3199
edges and 822 nodes. Consequently, the statistically significant triplets were mapped on to the
GRN. The results showed that the regulatory relations of 242 triplets are detectable in this
GRN.
Overall, the biological relevance of the 14 statistically significant triplets was defined by
both GRN and GSEA methods. The position of such triplets are shown as a subnetwork of
Fig 4. Pathway enrichment analysis. Enriched terms based on KEGG pathway (A) for each neurodegenerative disease (NDD)
separately; and (B) shared by at least five of the NDDs.
https://doi.org/10.1371/journal.pone.0239219.g004
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GRN in Fig 5. In addition, the liquid association analysis information of these triplets were
reported in Table 1. One of these triplets is the 1133nd triplet, which consists of genes Rps27a
and {Il18, Cx3cl1}. Although some triplets have a higher liquid association score than 1133nd
triplet, there is a feature that distinguishes such triplets from the other ones. 1133nd triplet is
the only statistically significant triplet that is not only biologically relevant based on both GRN
and GSEA analyses but also it is involved in 5 diseases (i.e., across all six NDDs except ALS).
On the other hand, the biological relevance of 1328nd triplet, which is involved in common
across all 6 NDDs, was confirmed only by GSEA method. This triplets consists of genes Bcl2
and {Ltbr, Il18}. The scatter plots of 1133nd and 1328nd triplets in three different ranges of
expression level of their associated X3 are presented in Fig 6. As shown, a considerable change
in the correlation of X1 and X2 occurs as a result of the changes in X3 expression level.
4 Discussion
Although different NDDs are clinically characterized with certain distinctive features, these
diseases exhibit share common neuropathological characteristics [34]. One such characteristic
is neuroinflammation which is associated with the immune system processes such as
Fig 5. The position of biologically relevant triplets in Gene Regulatory Network (GRN). The biological relevance of 14 statistically significant triplets
was confirmed by KEGG pathway enrichment analysis as well as GRN analysis. A subnetwork of GRN that includes the regulatory relations of such triplets
is shown here. Red nodes represent the X3 position gene in each triplet, green nodes represent the X1 and X2 position genes, and other genes are presented
by blue nodes.
https://doi.org/10.1371/journal.pone.0239219.g005
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inflammation and immune response. Previously, a number of studies investigated the molecu-
lar factor(s) of such common changes [11, 12]. However, to the best of our knowledge, no
pathway or gene was reported to be in common across all major NDDs. In the present study,
the three-way interaction model was used for to investigate the immune-related switch mecha-
nisms in NDDs. Our results suggests that a number of immune-related switch genes act variety
of different NDDs.
Table 1. Biologically relevant triplets.
X1 or X2 X2 or X1 X3 ρhigh ρlow ρdiff p-value adjusted p-value
Coro1a Cyba Ikbke 0.77 "" -0.58 "# 1.35 4.30E-11 8.60E-06
Traf3 Cyba Trem2 -0.11 "# -0.67 "# 0.56 8.09E-10 1.62E-04
Ticam1 Il18 Vipr1 -0.4 "# 0.77 "" -1.17 1.73E-08 3.46E-03
Itgb1 Coro1a Ikbke 0.51 "" -0.64 "# 1.15 1.89E-08 3.78E-03
Tnfrsf1a Coro1a Ikbke 0.65 "" -0.59 "# 1.24 2.31E-08 4.62E-03
Il18 Cx3cl1 Rps27a 0.37 "" -0.56 "# 0.93 2.39E-08 4.78E-03
Abl1 Hla-F Traf3 0.6 "" -0.27 "# 0.87 2.47E-08 4.94E-03
Tlr4 Abl1 Ltbr -0.12 "# 0.73 "" -0.85 2.90E-08 5.80E-03
Hla-E Coro1a Ikbke 0.6 "" -0.58 "# 1.18 2.99E-08 5.98E-03
Ticam1 C1qbp Plscr1 -0.6 "# 0.39 "" -0.99 3.07E-08 6.14E-03
Nfkb1 Coro1a Ikbke 0.57 "" -0.66 "# 1.23 3.21E-08 6.42E-03
Hla-E Hist2h2be Trim21 -0.38 "# 0.53 "" -0.91 3.33E-08 6.66E-03
Fyn Tnfrsf10b Ubb 0.64 "" -0.56 "# 1.20 3.53E-08 7.06E-03
Ccl21 Il18 Prkce 0.57 "" -0.66 "# 1.23 4.25E-08 8.50E-03
The liquid association analysis information of the 14 triplets that are statistically, as well as biologically, significant. The Pearson’s correlation coefficient of X1 and X2
when X3 is at a high gene expression level is indicated by ρhigh (i.e., rho{X1, X2}|X3") and when X3 is at a low gene expression level is indicated by ρlow (i.e., rho{X1, X2}|
X3"). In addition, ρdiff is the absolute value of their difference (i.e., ρdiff = |ρhigh-ρlow|). Arrows indicate direct ("") or inverse ("#) correlation of X1 and X2 in the specific
state of X3.
https://doi.org/10.1371/journal.pone.0239219.t001
Fig 6. Scatter plot of the two statistically significant and biologically relevant triplets. In each case, there is a
considerable change in the correlation of X1 and X2 as a result of change in X3 expression level.
https://doi.org/10.1371/journal.pone.0239219.g006
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As the mentioned above, the purpose of the present study was to perform a comparative
analysis on the involved mechanisms in NDDs. Because distinct regions of brain are affected
in different NDDs [35], there was an inevitable diversity among the brain regions from which
the samples are taken. On the other hand, several studies show that the properties of cell popu-
lation in samples depended on the region of brain [36]. Therefore, in order to reduce the vari-
ability between samples, a preprocessing and normalization step as the first stage was
performed. More specifically, the quantile normalization method [37] was utilized to minimize
the batch effects.
The results of eBayes t-test analysis suggest that the number of DEGs are strikingly different
among these diseases. The lowest and the highest number of immune-related DEGs belong to
AD and HD, respectively. This observation is consistent with the idea that beside a number of
morphological similarities, fundamental differences exist between the natures of these
diseases.
As shown in Fig 2, the observed event rate of X3 position (switch) genes in a wide range of
significant fastLA p-values is far greater than what is expected by chance. In other words, most
X3 positions in the statistically significant triplets are occupied by certain genes. Therefore
such result confirms the validity of fastLA analysis. In addition, in Fig 3, we show that such cer-
tain X3 positions genes are frequently belong to DEGs. As shown in Fig 3, the percentage of
the DEGs in the all of the immune genes is 25%, while the percentage of DEGs in the all of the
X3 position genes is 53%. This results shows that DEGs play a central role in the switch
mechanisms.
The results of the KEGG enrichment analysis (Fig 4) show that three pathways are com-
monly involved in at least five of the NDDs. These pathways include "osteoclast differentia-
tion", "natural killer cell mediated cytotoxicity" and "cytokine-cytokine receptor interaction".
In the following, the relationship between these pathways and NDDs is explained in detail.
4.1 Osteoclast differentiation
From its name, the osteoclast differentiation pathway seems to be an unrelated pathway to the
NDDs at the first sight. It is interesting to note that the link between osteoclast differentiation
pathway and the NDDs is suggested in numerous studies [38–43]. Previous studies reported
that the oncostatin M receptor signaling pathway, which is associated with NDDs [44, 45],
stimulates osteoclast differentiation [46, 47]. On the other hand, Sato and colleagues pointed
out donepezil, a typical drug for Alzheimer’s disease [48], inhibits osteoclast differentiation by
down regulating acetyl cholinesterase [49]. In addition, ROS are involved in Alzheimer’s dis-
ease as well as the osteoclasts differentiation pathway. Specifically, ROS, as redox signaling
intercellular molecules, are involved in regulating the osteoclast differentiation via receptor
activator of nuclear factor kappa β ligand. On the other hand, cytotoxic effect of ROS is associ-
ated with destruction of lipids, proteins and DNA in AD. In addition, previous studies
reported that the vesicle-associated membrane protein (VAMP)-associated protein B (VAPB)
[50–52], which is related to the osteoclast differentiation pathway, is involved in NDDs such as
ALS [53], and PD [54]. In fact, VAPB participates in death of motor neurons through ER stress
and impaired Ca2+ homeostasis [53]. Furthermore, VAPB regulates the osteoclast differentia-
tion pathway by adjusting NFATc1 [55].
4.2 Natural killer cell mediated cytotoxicity
Another enriched biological pathway for NDDs is "Natural killer cell mediated cytotoxicity"
(Fig 4). Natural killer (NK) cells are large granular lymphocytes that have cytotoxic properties
[56]. The cytotoxicity of NK cells is carried out a collectively by inhibitory and stimulatory
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receptors that are expressed on NK cells surface [57]. In addition, NK cells have a crucial role
in innate and adaptive immune system [58]. The central role of the NK cell activity in AD, MS,
PD and SCHIZ has been reported (see below).
Some evidence suggests that the NK cell activity in AD patients is significantly lower than
that in normal controls [59]. Moreover, the cytotoxic activity of NK cells is associated with
neurological inflammation observed in neuronal degeneration [60]. In addition, the NK cells
activity has been suggested as a biomarker for AD progression [61]. Likewise, the role of NK
cell in MS disease has been well studied [56, 62]. Uchida and colleagues showed that NK cell
activity in MS patients is significantly lower than that in normal ones. They also reported that
the interferon treatment of lymphocytes leads to an increase in the activity of NK cells that is
less than in MS patients compared to normal ones [63]. Chanvillard and colleagues showed
that mitoxantrone, a cytotoxic drug that is approved for treatment of progressive MS, induces
maturation of NK cells in patients with progressive MS [64]. Rodriguez-Martin and colleagues
reported that all NK cell subsets significantly increased in MS and other inflammatory neuro-
logical diseases compared to in non-inflammatory neuropathies [65]. In addition, Segal
reported that in MS, NK cells curb neuroinflammation by inhibiting the auto-reactive T cell
responses. In other words, NK cells by regulating of some adaptive immune responses, restricts
neuroinflammation in MS [66]. Furthermore, the role of NK cells in PD has been also studied.
Mihara and colleagues reported that expression of inhibitory receptor CD94/NKG2A was
remarkably lower in PD patients than those in non-PD individuals. Actually, inhibitory recep-
tor CD94/NKG2A suppresses activation signaling processes, which trigger after binding NK
cells with its ligand on the normal cells, to avoid destruction of normal bystander cells [67].
Therefore, because of limited number of such inhibitory receptor in PD patient and subse-
quently a deficiency in inhibition of NK cells activation in the normal cells, the PD patients are
prone to disruption of normal cells.[68]. Jiang and colleagues conducted a systematic review to
found relevance between lymphocyte subsets/NK cell and the risk of PD. Their results showed
that the number of NK cells significantly increased in PD; and consequently, such cells may be
associated with the risk of PD [69]. Additionally, there are numerous studies on the activation
of NK cells in SCHIZ. Schindler and colleagues compared the activity of NK cells in the blood
of SCHIZ patients and healthy controls, but they did not find significant differences between
the two groups [70]. On the other hand, Abdeljaber and colleagues reported that the activity of
NK cells in SCHIZ patients decline compared to the control group [71], although similar
results are not observed in other studies.
4.3 Cytokine-cytokine receptor interaction
Another biological pathway that is enriched in the six major NDDs is "cytokine-cytokine
receptor interaction" (Fig 4). Cytokines are produced by peripheral immunocompetent, glial
cells and neurons [72]. During immune responses, cytokines mediate specific signaling com-
munications between neurons and immune cells. Additionally, cytokines play pleiotropic roles
in the central nervous system, which include roles in synaptic plasticity, neurotransmission,
nuclear signal transduction, neurogenesis, and inflammatory responses [73, 74]. While the
pathophysiological role of cytokines in NDDs is well known [75], to our knowledge, the cyto-
kine-cytokine receptor interaction (CCRI) pathway was reported only in MS, SCHIZ, and AD
in previous studies. See below.
Xu and colleagues have previously indicated that the change in of Il-18 pathway may con-
tribute to psychopathology of SCHIZ. They also showed that the Il-18 pathway was strongly
associated with the CCRI pathway [74]. The relevance of the pathway to MS has been also
reported. Guo and colleagues, by comparison between blood transcriptome of MS and
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healthy individuals, showed that genes involved in the CCRI pathway were potentially associ-
ated with MS [76]. Likewise, about AD, Sattlecker and colleagues reported that the members
of CCRI pathway change during AD in proteome-level quantification [77]. On the other
hand, Khayer and colleagues reported that CCRI pathway is a critical switch pathway in trig-
gering AD [15].
4.4 Relationship between involved genes in triplet Rps27a, {Il-18, Cx3cl1}
The 1133nd triplet which contains of genes Rps27a and {Il-18, Cx3cl1} is one of the most statis-
tically significant triplets in our analysis. Furthermore, this triplet is found to be biologically
relevant, based on GSEA and GRN analyses (Table 1 and Fig 5). As shown in Fig 6, when nor-
malized expression level of Rps27a gene is between 0.40 and 2.39, there is an inverse correla-
tion between Il-18 and Cx3cl1 expression levels. In contrast, when normalized expression level
of Rps27a gene is between -2.39 and -0.40, there is a direct correlation between Il-18 and
Cx3cl1 expression levels. In other words, changes in expression level of Rps27a gene can act as
the switch factor for altering the regulated genes.
To the best of our knowledge, no previous study has investigated the role of Rps27a gene in
NDDs. Nevertheless, there is considerable evidence to support that Rps27a gene may be associ-
ated with this category of diseases.
Rps27a gene encodes a fusion protein consisting of ubiquitin (Ub) at the N terminus and
ribosomal protein S27a at the C terminus [78]. Rps27a protein is cleaved to free ubiquitin
monomer and ribosomal protein S27a by a cysteine protease, namely UCHL1 [79]. In other
words, UCHL1 is a deubiquitinating enzymes (DUBs).
Ub is a versatile regulatory protein that plays diverse roles in cells [80]. In addition, the
cellular Ub pool, which is composed of free Ub and Ub conjugates, are in dynamic equilib-
rium inside cells. On the other hand, the maintenance of cellular levels of Ub (i.e., Ub
homeostasis) is substantial for appropriate ubiquitination of substrate proteins [81]. Previ-
ous studies indicated that disruption of Ub homeostasis plays a critical role in the patho-
physiology of various NDDs [82–86]. There are at least two ways for maintaining Ub
homeostasis in cells. One of them is regulation of DUBs that convert Ub conjugates into
their monomeric free forms, and consequently increase the levels of Ub pool [87]. UCHL1, a
DUB enzyme for Rps27a (see previous paragraph), dysfunction is associated with a variety of
NDDs, including AD [88, 89], PD [90–92], HD [93, 94] and SD [95]. The other way is regu-
lation of gene expression of monomeric Ub-ribosomal fusion genes as well as polyubiquitin
genes. As mentioned above, Rps27a is a monomeric Ub-ribosomal fusion gene; therefore
regulation of such gene can be a way to maintain cellular Ub pool and in turn, might con-
tribute to NDDs.
As it was mentioned above, Il-18 and Cx3cl1 genes that are involved in triplet 1133nd are
directly correlated in some conditions. Surprisingly, the positive relationship between Il-18
and Cx3cl1 was reported in previous studies. Alboni and colleagues demonstrated that fluoxe-
tine, as a chronic antidepressant drug, that is involved in anti-inflammatory, anti-apoptotic
and antioxidant activity [96], decreases hypothalamic expression of Il-8 and Cx3cl1 genes
simultaneously [97]. On the other hand, both Il-18 and Cx3cl1 genes were suggested as inter-
feron-related biomarkers for Listeria monocytogenes by Koopmans and colleagues [98]. In
addition, Kasama and colleagues reported that gene expression levels of Cx3cl1 and Il-18 are
positively correlated with each other in adult-onset Still’s disease [99]. Furthermore, Bian and
collegues indicated that the interaction between Cx3cl1 and Il-18 signaling plays a critical role
in the development of allodynia [100].
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4.5 Cx3cl1 as a potential upstream regulator of Il-18 in microglia activation
Some evidence suggests that Cx3cl1might be as an upstream regulator of Il-18 in microglia
cells. See below.
Cx3cl1 and Il-18 genes are involved in spinal long term potentiation [101] as well as micro-
glia activation [102]. Bian and colleagues, by utilizing double immunostaining technique,
showed that Cx3cl1 receptor (Cx3cr1) is co-localized with Il-18 in the spinal cord and predomi-
nately expressed in spinal microglia in rats. They also reported that blockade of Cx3cl1/ Cx3cr1
signaling and/or Il-18, obviously suppresses the spinal long term potentiation [101]. On the
other hand, Miyoshi and colleagues determined that production of Il-18 in the spinal cord
was regulated by p38MAPK [103]. Furthermore, Zhang and colleagues reported that the
p38MAPK signaling was activated in spinal microglia by exposing to exogenous Cx3cl1 [104].
Therefore, it is reasonable to infer that Cx3cl1might act as a potential upstream regulator of Il-
18 in microglia cells.
Besides, some previous studies indicate that microglia activation is involved in spinal long
term potentiation [105, 106] as well as in NDDs [107]. It should be mentioned that the central
role of Il-18 gene in AD [108], ALS [109, 110], MS [111] and SD [74, 112, 113], and Cx3cl1
gene in all of the six surveyed diseases (i.e. AD [114, 115], ALS [116], HD [117], MS [118], PD
[119–122] and SD [123, 124]) has been determined. However, as far as our knowledge goes,
the relation between Il-18 and Cx3cl1 in triggering of NDDs is not reported in the literature
yet.
4.6 Investigation of DAM-like and primed-like expression program during
human neurodegeneration
Microglia, the central participator in the immune system of CNS, are versatile cells. Such cells,
depending on environment signals, can acquire different phenotypes [125]. Two novel known
subtypes of microglia that occur in mouse models of NDDs, are disease-associated microglia
(DAM) [126] and primed microglia [127]. In this section, we asked whether induction of a
DAM-like and/or primed-like expression program is traced in microglia of human NDDs. To
this end, we compared our results with recently published gene expression data of DAM and
primed microglia. See below.
Recently, Keren-Shaul and co-authors [126] reported a protective sub-type of microglia
associated with NDDs, termed disease-associated microglia (DAM), in AD and ALS mouse
model. They utilized single-cell RNA sequencing technique on microglia isolated from mouse
model of AD (5XFAD) and ALS (mSOD1 [G93A] mice) as well as the corresponding wild-
type mice. Subsequently, using graph-based clustering analysis, they identified a DAM gene
signature for mouse model of AD and ALS. We compared our results with DAM characteristic
genes to investigate the DAM-like expression program in human NDDs. Of the 22 DAM char-
acteristic genes, reported by Keren-Shaul and co-authors, 7 genes, including Cx3cr1, Tyrobp,
B2m, Fth1, Trem2, Axl and Csf1, were found in our results as involved genes in statistically sig-
nificant triplets. Additionally, Trem2, a key gene that enable the microglial progression to a full
activation DAM profile, was found in our results as a switch gene. On the other hand, they
highlighted lysosomal, phagocytic, and lipid metabolism pathways for DAM characteristic
genes. In a comparative aspect, none of DAM-related pathways were enriched in our study for
any disease. Taken together, there are not a striking overlap between DAM characteristic
genes and key genes reported in our study. Two possible reasons for such observation may be:
(i) differences in applied transcriptomic analysis techniques, which can affect the accuracy of
the study; (ii) differences in the nature of investigated samples. To the best of our knowledge, a
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slight genetic differences between mouse and human might be translated in to a salient distinc-
tion [128].
Another subtype of microglia that is reported for mouse model of NDDs is primed micro-
glia. Such subtype of microglia acquires a hypersensitive phenotype, becoming hyper-reactive
and secreting large amount of inflammatory mediators in response to signal from a systemic
inflammatory event [129]. Holtman and co-authors [127], to determine the gene expression
signature of priming, analyzed the transcriptome of microglia in mouse model of AD and ALS
using weighted gene co-expression network analysis. They identified four hub genes specific
for the primed microglia expression network, including Lgals3, Igf1, Csf1, and Axl. Interest-
ingly, all of hub genes except Igf1 were found in our results. These genes are involved in X3
position and/or X1, X2 of significant triplets. Hence, it can be expected that a primed-like
expression program triggers in human neurodegenerative diseases as in mouse model occurs.
However, our knowledge for such claim is not sufficient and more evidence is needed to sup-
port it.
5 Conclusion
Recent study is the first time that was utilized three-way interaction approach to survey com-
mon pathways in the NDDs. Three-way interaction approach is a promising strategy that pro-
vides new type of information on the specific relationships among genes. In conclusion, three
common switch pathways that include "osteoclast differentiation", "natural killer cell mediated
cytotoxicity" and "cytokine-cytokine receptor interaction" were found in the major NDDs.
More specifically, our analysis showed that Rps27a as the switch gene and the gene pair {Il-18,
Cx3cl1} form a statistically significant and biologically relevant triplet in the major NDDs.
Additionally, we suggested that Cx3cl1might act as a potential upstream regulator of Il-18 in
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